Sales and marketing expenses were $14.5 million in the fourth quarter and $63.2 million for the full year compared to $14 million and $64.6 million for the prior year periods respectively. This is mainly due to commissions rising with stronger revenue in both periods, offset by lower compensation, severance, consulting, and travel costs for the year.

Mar 24, 2026 / receipt, needs a key / Roberto Cuca, Chief Operating Officer and Chief Financ | earnings call 2026-03-24 | transcript 0ee97f40-17d4-47e7-a14d-337e335061f0 | chars 17799-18151 | segment 18

Sales and marketing expenses were $15.2 million in the third quarter compared to $16.5 million for the prior year period. This decrease was mainly due to lower compensation costs, consulting, and travel expenses, which were offset by higher commission expense on an increased revenue base.

Nov 13, 2025 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2025-11-13 | transcript 2e0c576a-6e74-47ab-8604-a1a96eb1a707 | chars 9274-9563 | segment 9

This increase was mainly due to higher commission expense on an increased revenue base, which offset lower compensation costs from a decrease in headcount and lower consulting and travel expenses.

Aug 11, 2025 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2025-08-11 | transcript 59189f07-31f9-4724-a7f4-aa5da6f7d268 | chars 15066-15262 | segment 15

So one of the things we came in initially and did is we revised the T&E policy to get in line with AVA Med guidelines, ensuring that everybody in our organization knew the rules of the road as well as what we had for budgets. That is a bottom line spend that we want to control, and we made everybody then take an SOP, revised SOP, as to signing off on the new T&E guidelines.

Aug 11, 2025 / receipt, needs a key / Jeff Blizzard, President | earnings call 2025-08-11 | transcript 59189f07-31f9-4724-a7f4-aa5da6f7d268 | chars 21615-21991 | segment 21

The decrease was primarily due to lower compensation costs from a decrease in headcount and lower consulting and travel expenses, which were partially offset by higher commission expense on an increased revenue base.

May 8, 2025 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2025-05-08 | transcript cb1f361d-bc9b-4bbb-92ac-33b1fc595c5f | chars 8634-8850 | segment 8

This increase was mainly due to higher compensation costs primarily from increased commissions and severance costs, increased travel and consulting, and additional selling-related expenses, which offset decreases in marketing expenses.

Mar 21, 2025 / receipt, needs a key / Roberta Kuka, COO and CFO | earnings call 2025-03-21 | transcript 94f9b6a8-712f-40a3-bf30-9e0416534d65 | chars 15033-15268 | segment 15

Sales and marketing expense was $16.5 million in the third quarter of 2024 compared to $14.5 million in the same period in 2023. The increase was primarily due to increased compensation costs, including increased severance costs and additional consulting and travel expenses.

Nov 7, 2024 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2024-11-07 | transcript 87d73788-d7f4-4407-9f19-bde392781b6a | chars 8163-8438 | segment 8

Sales and marketing expense was $16.7 million in the second quarter of 2024 compared to $14.6 million in the same period in 2023. This increase was mainly due to higher compensation costs as a result of our expanded commercial organization, increased travel expenses, and a marketing distribution fee which offset lower marketing expense.

Aug 12, 2024 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2024-08-12 | transcript b4e02511-8719-453c-a88d-546a6799a3bb | chars 10841-11179 | segment 10

Sales and marketing expense was $17.5 million in the first quarter of 2024 compared to $13.5 million in the same period in 2023. This increase was mainly due to higher compensation costs as a result of the expansion of our commercial organization higher travel and consulting expenses, and additional employee-related costs due to increased headcount.

May 9, 2024 / receipt, needs a key / Roberto Cuca, CFO | earnings call 2024-05-09 | transcript 26fc0b19-189d-4f61-a20a-e8a593c44ae3 | chars 8215-8566 | segment 7

Sales and marketing expense was $17.2 million in the fourth quarter of 2023 compared to $11.6 million in the same period in 2022. This increase was mainly due to higher salary, benefit, and commission costs as a result of the expansion of our commercialization organization, higher travel and consulting expenses, and additional employee-related costs due to increased headcount.

Mar 21, 2024 / receipt, needs a key / Roberto Cuca, COO and CFO | earnings call 2024-03-21 | transcript 196eec83-6192-4933-86bd-984ec1cbe44a | chars 10141-10520 | segment 10

This increase was a result of additional headcount as we continue to expand our organization, consequent higher compensation and employee-related expenses, increased travel expense, as well as an increase in consulting fees and higher study costs.

Nov 9, 2023 / receipt, needs a key / Roberta Kuka, CFO | earnings call 2023-11-09 | transcript d2862152-8295-45b5-bb4f-6cb93b522258 | chars 11632-11879 | segment 11

The increase was mainly due to higher compensation costs as a result of the expansion of our commercial organization, higher travel and consulting expenses, and additional employee-related costs due to increased headcount, particularly in our customer-facing roles.

Aug 9, 2023 / receipt, needs a key / Roberto Cuca, Chief Operating Officer and Chief Financ | earnings call 2023-08-09 | transcript 60197c39-888a-4d34-ba07-c3a4bd1a29d0 | chars 9485-9750 | segment 9

We believe that the virtual meeting format enables stockholders to attend and participate from any location around the world at no cost, provides for cost savings to TELA Bio, Inc. and our stockholders, and reduces the environmental impact of our Special Meeting.

filing / Sep 14, 2026 / receipt

Antony Koblish stepped down from his position as the Company’s Chief Executive Officer

filing / Sep 14, 2026 / receipt

Roberto Cuca stepped down from his position as the Company’s Chief Financial Officer

filing / Sep 14, 2026 / receipt